British Journal of Haematology · 2002 · 69 citations · 44 references
MedicineHematologyImmunologyApoptosisImmunoregulationRheumatologyCytokine-mediated PathologyInflammatory SignalingMyelodysplastic SyndromesRheumatoid ArthritisBlood Cell DisordersBone Marrow - Derived CellsImmune Suppression MechanismsMyelodysplastic Syndrome TherapyMyelodysplastic Syndrome TreatmentRheumatoid Arthritis TherapyTumor Necrosis Factor Inhibitor TherapyTumor Necrosis Factor Therapy
Laboratory observations suggest that, in some myelodysplastic syndromes (MDS), immune mechanisms may contribute to the impaired blood cell production. Tumor necrosis factor alpha (TNF-alpha), a potent inhibitor of haematopoiesis, has been hypothesized to mediate suppressive effects in MDS: TNF-alpha levels are elevated and correlated with marrow apoptosis and cytopenia. Inhibition of TNF-alpha production using the soluble TNF receptor (Enbrel) has been successful in rheumatoid arthritis, and we have now applied the same principle to MDS. We determined spontaneous TNF-alpha production by marrow cells in MDS; TNF-alpha production was elevated (> mean + 2 x SD of controls) in > 1/3 of patients, but did not correlate with clinical parameters. Sixteen patients participated in a 3-month pilot study of Enbrel. The drug was well tolerated and 15 patients were evaluable. Of these, one became temporarily (14 weeks) transfusion independent. In another patient, absolute neutrophil count (ANC) rose from 0.5 x 10(9)/l to 0.84 x 10(9)/l. Serious infections were seen in two out of six neutropenic patients. Progression to refractory anaemia with excess blasts in transformation (RAEBt) or leukaemia was observed in three patients. When the effects of Enbrel on haematopoietic colony formation were studied, no significant increase was seen in MDS and there was no correlation with TNF-alpha levels. Although anti-TNF therapy with Enbrel was well tolerated at the dosages used in MDS, its efficacy as a single agent appears low.
44
International Scoring System for Evaluating Prognosis in Myelodysplastic Syndromes
Peter L. Greenberg, Christopher Cox, Michelle M. LeBeau et al. · Blood · 1997 · 4.5K citations · Full text
Proposals for the classification of the myelodysplastic syndromes
John M. Bennett, Daniel Catovsky, MT Daniel et al. · British Journal of Haematology · 1982 · 3.7K citations
Medicine, Hematology, Pathology +12
Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial
Philip J. Mease, Bernard S. Goffe, James M. Metz et al. · The Lancet · 2000 · 1.5K citations
Etanercept in Children with Polyarticular Juvenile Rheumatoid Arthritis
Daniel J. Lovell, Edward H. Giannini, Andreas Reiff et al. · New England Journal of Medicine · 2000 · 1.3K citations · Full text
Medicine, Immunology, Pediatrics +7